Australia
· Delayed Price · Currency is AUD Clarity Pharmaceuticals Statistics
Total Valuation
Clarity Pharmaceuticals has a market cap or net worth of AUD 2.24 billion. The enterprise value is 2.11 billion.
| Market Cap | 2.24B |
| Enterprise Value | 2.11B |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Clarity Pharmaceuticals has 320.21 million shares outstanding. The number of shares has increased by 5.22% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 320.21M |
| Shares Change (YoY) | +5.22% |
| Shares Change (QoQ) | +8.57% |
| Owned by Insiders (%) | 17.84% |
| Owned by Institutions (%) | 12.39% |
| Float | 224.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 166.41 |
| PB Ratio | 14.93 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -49.81 |
| EV / Sales | 183.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -48.20 |
Financial Position
The company has a current ratio of 19.05
| Current Ratio | 19.05 |
| Quick Ratio | 18.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.29% and return on invested capital (ROIC) is -25.99%.
| Return on Equity (ROE) | -39.29% |
| Return on Assets (ROA) | -24.19% |
| Return on Capital (ROIC) | -25.99% |
| Revenue Per Employee | 230,133 |
| Profits Per Employee | -846,489 |
| Employee Count | 50 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +520.35% in the last 52 weeks. The beta is 1.58, so Clarity Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | +520.35% |
| 50-Day Moving Average | 7.46 |
| 200-Day Moving Average | 5.13 |
| Relative Strength Index (RSI) | 47.98 |
| Average Volume (20 Days) | 1,332,508 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Clarity Pharmaceuticals had revenue of AUD 11.51 million and -42.32 million in losses. Loss per share was -0.15.
| Revenue | 11.51M |
| Gross Profit | 11.51M |
| Operating Income | -44.80M |
| Pretax Income | -42.03M |
| Net Income | -42.32M |
| EBITDA | -44.65M |
| EBIT | -44.80M |
| Loss Per Share | -0.15 |
Balance Sheet
| Cash & Cash Equivalents | 136.51M |
| Total Debt | n/a |
| Net Cash | 136.51M |
| Net Cash Per Share | 0.43 |
| Equity (Book Value) | 146.30M |
| Book Value Per Share | 0.47 |
| Working Capital | 145.97M |
Cash Flow
In the last 12 months, operating cash flow was -43.24 million and capital expenditures -504,005, giving a free cash flow of -43.74 million.
| Operating Cash Flow | -43.24M |
| Capital Expenditures | -504,005 |
| Free Cash Flow | -43.74M |
| FCF Per Share | -0.14 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -389.35% |
| Pretax Margin | -365.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -380.14% |
Dividends & Yields
Clarity Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.22% |
| Shareholder Yield | -5.22% |
| Earnings Yield | -2.21% |
| FCF Yield | -1.95% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Clarity Pharmaceuticals has an Altman Z-Score of 43.45.
| Altman Z-Score | 43.45 |
| Piotroski F-Score | n/a |